Indisulam: an anticancer sulfonamide in clinical development

Indisulam (N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide, E7070) is a novel sulfonamide anticancer agent in clinical development for the treatment of solid tumours. Its mechanism of action is multifactorial, as indisulam arrests cell cycle in the G1 phase, strongly inhibits carbonic anhydrase, a critical enzyme involved in many physiological processes and whose association with cancer became obvious in the last period, and markedly alters gene expression levels of at least 60 transcripts. Four Phase I clinical trials gave promising results, showing the compound to possess nonlinear pharmacokinetics. Presently this compound is in Phase II trials in Europe and USA for the treatment of solid tumours.

[1]  Claudiu T. Supuran,et al.  Applications of carbonic anhydrase inhibitors and activators in therapy , 2002 .

[2]  T. Owa,et al.  Novel sulphonamide derivatives for the treatment of cancer , 2000 .

[3]  T. Owa,et al.  E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. , 2001, European journal of cancer.

[4]  T. Owa,et al.  Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents. , 2002, Bioorganic & medicinal chemistry letters.

[5]  J. Wanders,et al.  Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Owa,et al.  Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. , 1999, Journal of medicinal chemistry.

[7]  A. Casini,et al.  Sulfonamides and sulfonylated derivatives as anticancer agents. , 2002, Current cancer drug targets.

[8]  Claudiu T. Supuran,et al.  Carbonic anhydrase inhibitors and their therapeutic potential , 2000 .

[9]  C. Supuran,et al.  Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? , 2001, Bioorganic & medicinal chemistry.

[10]  J. Wanders,et al.  Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Punt,et al.  Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Schellens,et al.  E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. , 2002, Anti-cancer drugs.

[13]  J. Usuda,et al.  Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells , 2004, Investigational New Drugs.

[14]  T. Owa,et al.  A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[15]  THE ROLES OF CARBONIC ANHYDRASE ISOZYMES IN CANCER , 2001 .

[16]  T. Owa,et al.  Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide. , 2002, Journal of medicinal chemistry.

[17]  T. Owa,et al.  Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. , 2002, Molecular cancer therapeutics.